[go: up one dir, main page]

MX2013001866A - Agonistas de receptor de prostaglandina suptipo-2(ep2) o receptor de prostaglandina suptipo-4(ep4) para tratar la opacidad de la cornea - Google Patents

Agonistas de receptor de prostaglandina suptipo-2(ep2) o receptor de prostaglandina suptipo-4(ep4) para tratar la opacidad de la cornea

Info

Publication number
MX2013001866A
MX2013001866A MX2013001866A MX2013001866A MX2013001866A MX 2013001866 A MX2013001866 A MX 2013001866A MX 2013001866 A MX2013001866 A MX 2013001866A MX 2013001866 A MX2013001866 A MX 2013001866A MX 2013001866 A MX2013001866 A MX 2013001866A
Authority
MX
Mexico
Prior art keywords
corneal haze
agonists
treating corneal
methods
compositions
Prior art date
Application number
MX2013001866A
Other languages
English (en)
Inventor
Larry A Wheeler
Scott M Whitcup
Wha Bin Im
Guang-Liang Jiang
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44511608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013001866(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2013001866A publication Critical patent/MX2013001866A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/539—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more oxygen atoms in the same ring, e.g. dioxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se describen composiciones y métodos para tratar la opacidad de la córnea Las composiciones y métodos de uso comprenden cantidades terapéuticamente efectivas de los compuestos que agoniza el receptor de EP2 y/o de EP4 La administración de los compuestos descritos puede prevenir y tratar el desarrollo de la opacidad de la cornea
MX2013001866A 2010-08-17 2011-08-17 Agonistas de receptor de prostaglandina suptipo-2(ep2) o receptor de prostaglandina suptipo-4(ep4) para tratar la opacidad de la cornea MX2013001866A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37443910P 2010-08-17 2010-08-17
PCT/US2011/048048 WO2012024376A1 (en) 2010-08-17 2011-08-17 Ep2 or ep4 agonists for treating corneal haze

Publications (1)

Publication Number Publication Date
MX2013001866A true MX2013001866A (es) 2013-05-22

Family

ID=44511608

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001866A MX2013001866A (es) 2010-08-17 2011-08-17 Agonistas de receptor de prostaglandina suptipo-2(ep2) o receptor de prostaglandina suptipo-4(ep4) para tratar la opacidad de la cornea

Country Status (13)

Country Link
US (1) US20120046332A1 (es)
EP (1) EP2605777A1 (es)
JP (1) JP2013534251A (es)
KR (1) KR20140003395A (es)
CN (1) CN103167875A (es)
BR (1) BR112013003600A2 (es)
CA (1) CA2808407A1 (es)
CL (1) CL2013000484A1 (es)
MX (1) MX2013001866A (es)
RU (1) RU2013111281A (es)
SG (1) SG187861A1 (es)
WO (1) WO2012024376A1 (es)
ZA (1) ZA201301196B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL270021B (en) 2017-04-18 2022-08-01 Tempest Therapeutics Inc Bicyclic compounds and their use in the treatment of cancer
DK3781550T3 (da) * 2018-04-17 2025-01-27 Tempest Therapeutics Inc Bicykliske carboxamider og fremgangsmåder til anvendelse deraf

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360611A (en) * 1988-10-03 1994-11-01 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following ultraviolet laser irradiation
US6875787B2 (en) 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
MXPA05008431A (es) * 2003-02-11 2005-10-19 Allergan Inc Derivados de acido 10,10-dialquil prostanoico como agentes para reducir la presion intraocular.
US7855226B2 (en) 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
US7015243B2 (en) * 2003-08-28 2006-03-21 Allergan, Inc. Cyclohexyl prostaglandin analogs as EP4-receptor agonists
EP1723132A1 (en) * 2004-02-12 2006-11-22 Asterand Uk Limited Ep2 receptor agonists
US7183324B2 (en) * 2004-11-23 2007-02-27 Allergan, Inc. 2,3,4-substituted cyclopentanones as therapeutic agents
RU2412933C2 (ru) * 2005-03-10 2011-02-27 Аллерган, Инк. Замещенные гамма-лактамы в качестве терапевтических агентов
RS20090002A (sr) * 2006-07-28 2010-06-30 Pfizer Products Inc. Agonisti ep2
WO2009146408A1 (en) * 2008-05-30 2009-12-03 Summa Health Systems Llc Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US20110052695A1 (en) * 2009-04-20 2011-03-03 Allergan, Inc. Drug delivery platforms comprising silk fibroin hydrogels and uses thereof
US20110111031A1 (en) * 2009-04-20 2011-05-12 Guang-Liang Jiang Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair

Also Published As

Publication number Publication date
ZA201301196B (en) 2014-04-30
SG187861A1 (en) 2013-03-28
BR112013003600A2 (pt) 2016-08-16
CN103167875A (zh) 2013-06-19
JP2013534251A (ja) 2013-09-02
CA2808407A1 (en) 2012-02-23
US20120046332A1 (en) 2012-02-23
EP2605777A1 (en) 2013-06-26
WO2012024376A1 (en) 2012-02-23
CL2013000484A1 (es) 2013-05-10
RU2013111281A (ru) 2014-09-27
KR20140003395A (ko) 2014-01-09

Similar Documents

Publication Publication Date Title
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
MX2013008192A (es) Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
PH12012501783A1 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
PH12012501739A1 (en) Treatment of lupus nephritis using laquinimod
IN2015DN01197A (es)
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
IN2015DN00542A (es)
MX338489B (es) Derivados de hidantoina utiles como inhibidores de kv3.
IN2015DN01161A (es)
NZ748451A (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
UA115983C2 (uk) Інгібітори днк-пк
IN2014CN03555A (es)
WO2012068106A3 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
PH12012501741A1 (en) Treatment of lupus arthritis using laquinimod
MY169479A (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MX360774B (es) Antagonistas de progesterona.
MX356813B (es) Derivados de hidantoina utiles como inhibidores de kv3.
PH12014501032A1 (en) 2-thiopyrimidinones
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
WO2011129936A3 (en) Compositions and methods for the prevention and treatment of cancer
MX348311B (es) Inhibidores nampt.
MX2012000006A (es) L-serina para usarse como un farmaco para prevenir y/o tratar una respuesta inflamatoria de la piel.
MX2014013758A (es) Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.